Rett syndrome

Active Ingredient: Trofinetide

Indication for Trofinetide

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

Trofinetide is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.

For this indication, competent medicine agencies globally authorize below treatments:

5,000-12,000 mg twice daily based on patient's body weight

For:

Dosage regimens

Regimen A: In case that patient weight is ≥ 9 kg and patient weight is ≤ 12 kg, oral, 5,000 milligrams trofinetide, 2 times daily.

Regimen B: In case that patient weight is ≥ 12 kg and patient weight is ≤ 20 kg, oral, 6,000 milligrams trofinetide, 2 times daily.

Regimen C: In case that patient weight is ≥ 20 kg and patient weight is ≤ 35 kg, oral, 8,000 milligrams trofinetide, 2 times daily.

Regimen D: In case that patient weight is ≥ 35 kg and patient weight is ≤ 50 kg, oral, 10,000 milligrams trofinetide, 2 times daily.

Regimen E: In case that patient weight is ≥ 50 kg, oral, 12,000 milligrams trofinetide, 2 times daily.

Detailed description

Administer trofinetide orally twice daily, in the morning and evening, according to patient weight as shown in the following table.

Recommended dosage of trofinetide in patients 2 years of age and older:

Patient weight Trofinetide dosage
9 kg to less than 12 kg 5,000 mg twice daily
12 kg to less than 20 kg 6,000 mg twice daily
20 kg to less than 35 kg 8,000 mg twice daily
35 kg to less than 50 kg 10,000 mg twice daily
50 kg or more 12,000 mg twice daily

Missed dose or vomiting after administration

If a dose of trofinetide is missed, the next dose should be taken as scheduled. Doses should not be doubled.

If vomiting occurs after trofinetide administration, an additional dose should not be taken. Instead, continue with the next scheduled dose.

Dose modification for diarrhea or weight loss

Advise patients to stop laxatives before starting trofinetide. Interrupt, reduce the dosage, or discontinue trofinetide if severe diarrhea occurs, if dehydration is suspected, or if significant weight loss occurs.

Dosage considerations

Trofinetide can be taken with or without food.

Administer trofinetide orally or via gastrostomy (G) tube; doses administered via gastrojejunal (GJ) tubes must be administered through the G-port.

A calibrated measuring device, such as an oral syringe or oral dosing cup, should be obtained from the pharmacy to measure and deliver the prescribed dose accurately. A household measuring cup is not an adequate measuring device.

Active ingredient

Trofinetide

Trofinetide is indicated for the treatment of Rett syndrome. The mechanism by which trofinetide exerts its therapeutic effects is unknown.

Read more about Trofinetide

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.